Nakagawa T, Muramoto Y, Hori M, Mihara S, Marubayashi T, Nakagawa K.
A preliminary investigation of the association between haptoglobin polymorphism, serum ferritin concentration and fatty liver disease.
Clin Chim Acta. 398, 34-38, 2008.

Mitani Y, Sato K, Muramoto Y, Karakawa T, Kitamado M, Iwanaga T, Nabeshima T, Maruyama K, Nakagawa K, Ishida K, Sasamoto K.
Superoxide scavenging activity of pirfenidone-iron complex.
Biochem Biophys Res Commun. 372, 19-23, 2008.

Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K.
Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
Br J Clin Pharmacol. 66, 304-307, 2008.

Oniki K, Umemoto Y, Nagata R, Hori M, Mihara S, Marubayashi T, Nakagawa K.
Glutathione S-transferase A1 polymorphism as a risk factor for smoking-related type 2 diabetes in Japanese.
Toxicol Lett. 178, 143-145, 2008.

Oniki K, Hori M, Takata K, Yokoyama T, Mihara S, Marubayashi T, Nakagawa K.
Association between glutathione S-transferase A1, M1 and T1 polymorphisms and hypertension.
Pharmacogenet Genomics. 18, 275-277, 2008.

Fukushima Y, Seo T, Hashimoto N, Higa Y, Ishitsu T, Nakagawa K.
Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes are risk factors for elevated serum γ-glutamyltransferase in valproic acid-treated patients.
Clin Chim Acta. 389, 98-102, 2008.

Seo T, Ishitsu T, Oniki K, Abe T, Shuto T, Nakagawa K.
ABCC2 haplotype is not associated with drug-resistant epilepsy.
J Pharm Pharmacol. 60, 631-635, 2008.

Seo T, Pahwa P, McDuffie HH, Yurube K, Egoshi M, Umemoto Y, Ghosh S, Fukushima Y, Nakagawa K.
Association between cytochrome P450 3A5 polymorphism and the lung function in Saskatchewan grain workers.
Pharmacogenet Genomics. 18, 487-493, 2008.

Goto S, Seo T, Hagiwara T, Ueda K, Yamauchi T, Nagata S, Ando Y, Ishitsu T, Nakagawa K.　
Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
J Pharm Pharmacol. 60, 267-272, 2008.

Seo T, Pahwa P, McDuffie HH, Nakada N, Goto S, Ghosh S, Nakagawa K.
Interactive effect of paraoxonase-1 Q192R polymorphism and smoking history on the lung function decline in grain workers.
Ann Epidemiol. 18, 330-334, 2008.

Seo T, Nagata R, Ishitsu T, Murata T, Takaishi C, Hori M, Nakagawa K.
Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
Pharmacogenomics. 9, 527-537, 2008.

Okada Y, Seo T, Wanibuchi A, Hashimoto N, Higa Y, Ishitsu T, Nakagawa K.
Population estimation of the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
Ther Drug Monit. 30, 540-543, 2008.

Karakawa T, Sato K, Muramoto Y, Mitani Y, Kitamado M, Iwanaga T, Nabeshima T, Maruyama K, Nakagawa K, Ishida K, Sasamoto K.
Applicability of new spin trap agent, 2-diphenylphosphinoyl-2-methyl-3,4-dihydro- 2H-pyrrole N-Oxide, in biological system.
Biochem Biophys Res Commun. 370, 93-97, 2008.